Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo
1 other identifier
observational
300
1 country
1
Brief Summary
This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedFirst Submitted
Initial submission to the registry
July 16, 2018
CompletedFirst Posted
Study publicly available on registry
August 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2019
CompletedApril 24, 2025
July 1, 2022
12 months
July 16, 2018
April 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Central obesity as a Metabolic risk in vitiligo patients
Central obesity will be assessed using waist circumference in cm in vitiligo patients and control group as a risk factor for metabolic syndrome
one year
Secondary Outcomes (8)
Arterial Blood Pressure as a Metabolic risk in vitiligo patients
one year
Fasting Blood pressure as a Metabolic risk in vitiligo patients
one year
Serum Triglycerides and HDL
one year
Body mass index as a Metabolic risk in vitiligo patients
one year
Detection of insulin resistance in patients with vitiligo
one year
- +3 more secondary outcomes
Study Arms (2)
Vitiligo patients
Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
controls
Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
Interventions
Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
Eligibility Criteria
Vitiligo patients presenting to Dermatology outpatient clinic (Kasr Alainy Teaching Hospitals, Cairo University).
You may qualify if:
- Both genders
- Patients with non-segmental vitiligo (NSV) and segmental vitiligo
You may not qualify if:
- Smoking
- Pregnancy
- Systemic steroid intake in the last 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Cairo university hospitals, dermatology outpatient clinic
Cairo, Egypt
Related Publications (1)
Ibrahim S, El-Tahlawi S, Mogawer RM, El Ansary M, Esmat S, El-Hawary M. Different vitiligo characteristics as predictors of increased risk of metabolic syndrome and insulin resistance: A case-control study. J Cosmet Dermatol. 2022 Dec;21(12):7170-7177. doi: 10.1111/jocd.15446. Epub 2022 Oct 25.
PMID: 36208004DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Samar El-Tahlawi, MD
Cairo university, dermatology department
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
July 16, 2018
First Posted
August 9, 2018
Study Start
July 1, 2018
Primary Completion
June 30, 2019
Study Completion
June 30, 2019
Last Updated
April 24, 2025
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share